Ellen Filvaroff

7.6k citations

66 papers · 5.5k indexed · 3 hit papers · h-index 29

Impact in

Urology top 1%
- Periodontal Regeneration and Treatments
Rheumatology top 1%
- Osteoarthritis Treatment and Mechanisms

Papers in

Immunology and Allergy 4
Oncology 18
- Bone health and treatments 4

Co-authors: Richard A.D. Carano Rik Derynck Adrian Erlebacher Stephen E. Gitelman Min Bao Jeffrey L. Cleland Stuart Bunting Hope Steinmetz
Journals: Annals of Oncology (7 papers)Molecular and Cellular Biology (5 papers)Human Immunology (4 papers)Proceedings of the National Academy of Sciences (3 papers)Journal of Clinical Oncology (3 papers)
Partner nations: United States Spain France

In The Last Decade

Ellen Filvaroff

66 papers receiving 5.4k citations

Hit Papers

align trajectories log scale

Angiogenesis and bone repair 2003 · 589 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2003 Drug Discovery Today
2002 Proceedings of the National Academy of Sciences
1995 Cell

Peers

Countries citing papers authored by Ellen Filvaroff

Since Specialization

Citations

This map shows the geographic impact of Ellen Filvaroff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Filvaroff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Filvaroff more than expected).

Fields of papers citing papers by Ellen Filvaroff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Filvaroff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Filvaroff. The network helps show where Ellen Filvaroff may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ellen Filvaroff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ellen Filvaroff Line = papers co-authored together Ellen Filvaroff links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Shallow shotgun sequencing reduces technical variation in microbiome analysis Scientific Reports ·Rosyidatuzzahro Anisyukurillah, Noah Strom, Ellen Filvaroff, Konstantinos Mavrommatis, Tonya Ward, Dan Knights	2023	23
2	18O CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study Annals of Oncology ·Antoine Hollebecque, Johann S. de Bono, Stefania Salvagni, Ruth Plummer, Patricia Niccoli, Amna Nsyif Jasim, Giuseppe Curigliano, Víctor Moreno, Filippo de Braud, M. López-Brea, Patricia Martín-Romano, Éric Baudin, 智子米田, W.P.A. Sudharika, Josep Lluís Parra-Palau, 戴正凤, Ida Aronchik, Ellen Filvaroff, M. Lamba, Zariana Nikolova	2020	3
3	527O CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study Annals of Oncology ·Víctor Moreno, Irene Braña, Juan Manuel Sepúlveda-Sánchez, María Vieito, Atılay Morgül, Bernard Doger, Omar Saavedra, Carmelo Carlo‐Stella, Jean‐Marie Michot, Antoîne Italiano, Gerardo Musuraca, Rosiane Luz Calvacante, Sheila Moran, Suhandy Tjahyono, 戴正凤, Ida Aronchik, Ellen Filvaroff, Bishoy Hanna, Zariana Nikolova, Antonio Pinto	2020	1
4	559P Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC) Annals of Oncology ·Luis Paz‐Ares, Óscar Juan, Enric Carcereny, Laurent Greillier, Alejandro Navarro, Jaafar Bennouna, Armando Santoro, Rossana Berardi, Benjamin Besse, Stefania Salvagni, 岳书华, W.P.A. Sudharika, Josep Lluís Parra-Palau, 戴正凤, Ida Aronchik, Ellen Filvaroff, M. Lamba, Zariana Nikolova, Santiago Ponce	2020	2
5	16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL) Annals of Oncology ·Víctor Moreno, Irene Braña, Juan Manuel Sepúlveda-Sánchez, María Vieito, P. Buszewski, Bernard Doger, Omar Saavedra, Antonio Pinto, Carmelo Carlo‐Stella, Antoîne Italiano, Jean‐Marie Michot, Gerardo Musuraca, Rosiane Luz Calvacante, W.P.A. Sudharika, Marlene Zuraek, 戴正凤, Ida Aronchik, Ellen Filvaroff, Bishoy Hanna, Zariana Nikolova	2020	3
6	Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma Annals of Oncology ·Víctor Moreno, Juan Manuel Sepúlveda-Sánchez, María Vieito, Atılay Morgül, Bernard Doger, Omar Saavedra, Blossom R. Primer, Rosiane Luz Calvacante, 智子米田, W.P.A. Sudharika, Alexandra Patzelt, Marlene Zuraek, 戴正凤, Ida Aronchik, Ellen Filvaroff, M. Lamba, Bishoy Hanna, Zariana Nikolova, Irene Braña	2020	50
7	<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p> Cancer Management and Research ·Pamela N. Münster, Monica Mita, Amit Mahipal, John Nemunaitis, Christophe Massard, Tom Mikkelsen, Cristina Cruz, Luis Paz‐Ares, Manuel Hidalgo, Dana E. Rathkopf, George Blumenschein, David C. Smith, Barbara Eichhorst, Tim Cloughesy, Ellen Filvaroff, Shaoyi Li, Heather K. Raymon, Gregory B Diette, Kristen Hege, Johanna C. Bendell	2019	67
8	Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance Molecular Cancer Research ·Ida Aronchik, Yumin Dai, Κωνσταντίνος Ζέρβας, Carmen Barnes, PETER F. HAGAN, Lixin Qiao, 正江倉員, A. Jain, Winfried Elis, Tao Shi, Konstantinos Mavrommatis, Gordon L. Bray, Ellen Filvaroff	2018	26
9	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia Blood ·Rachel Thijssen, F. El-Thewey, Є. М. Мокрий, Y.K. Kim, Jennifer R. Brown, Stacey M. Fernandes, Francico Jesús Ferreiro Seoane, Jean‐Marie Michot, Michael Hallek, Barbara Eichhorst, Hans Christian Reinhardt, Johanna C. Bendell, Ingrid A. M. Derks, Roel J.W. van Kampen, Kristen Hege, Marie José Kersten, Torsten Trowe, Ellen Filvaroff, Eric Eldering, Arnon P. Kater	2016	59
10	MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation EBioMedicine ·Акимова М.А., Ellen Filvaroff, Jing Peng, Scot A. Marsters, Adrian M. Jubb, Hartmut Koeppen, Mark Merchant, Avi Ashkenazi	2015	13
11	Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab Molecular Cancer Therapeutics ·Elaine Mai, Zhong Zheng, Youjun Chen, Jing Peng, Christophe Severin, Ellen Filvaroff, Mally Romero, William Mallet, Surinder Kaur, Thomas Gelzleichter, Ihsan Nijem, Mark Merchant, Judy Young	2013	10
12	Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors Cancer Research ·Sabban, Yuwen Zhang, Yanli Su, 문광섭, Sharianne G. Louie, Christophe Severin, Nerissa Mendoza, Zhong Zheng, T F Dekoning, Dafna Kaufman, George Vande Woude, Jiping Zha, Robert L. Yauch, Ellen Filvaroff	2008	9
13	Albumin Stimulates the Accumulation of Extracellular Matrix in Renal Tubular Epithelial Cells American Journal of Nephrology ·Jean-Philippe Stéphan, Weiguang Mao, Ellen Filvaroff, Liping Cai, Ralph Rabkin, Guohua Pan	2003	33
14	Angiogenesis and bone repair Drug Discovery Today ·Richard A.D. Carano, Ellen Filvaroff Hit paper breakdown →	2003	589
15	Osteoblastic Responses to TGF-β during Bone Remodeling Molecular Biology of the Cell ·Adrian Erlebacher, Ellen Filvaroff, Yuri Kitamura, Rik Derynck	1998	189
16	Expression of a Truncated, Kinase-Defective TGF-β Type II Receptor in Mouse Skeletal Tissue Promotes Terminal Chondrocyte Differentiation and Osteoarthritis The Journal of Cell Biology ·Rosa Serra, Mahlon D. Johnson, Ellen Filvaroff, James B. LaBorde, Daniel M. Sheehan, Rik Derynck, Harold L. Moses	1997	381
17	Induction of Myogenesis in Mesenchymal Cells by MyoD Depends on Their Degree of Differentiation Developmental Biology ·Ellen Filvaroff, Rik Derynck	1996	11
18	Toward a molecular understanding of skeletal development Cell ·Adrian Erlebacher, Ellen Filvaroff, Stephen E. Gitelman, Rik Derynck Hit paper breakdown →	1995	572
19	Bioengineered soluble HLA-B7 Human Immunology ·Debra D. Hiraki, Ron Zegers, Ellen Filvaroff, 久光西, Soon Yong Choi, Annisa Annisa, Kjerstii Aagaard	1994	21
20	Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization Human Immunology ·F. Carl Grumet, 久光西, Ron Zegers, Ellen Filvaroff, Debra D. Hiraki	1994	28

About Ellen Filvaroff

Ellen Filvaroff is a scholar working on Immunology and Allergy, Oncology, Molecular Biology, Rheumatology and Hepatology, having authored 66 papers that have together received 5.5k indexed citations. Recurring topics across this work include TGF-β signaling in diseases (11 papers), Bone Metabolism and Diseases (10 papers), Histone Deacetylase Inhibitors Research (6 papers), Cancer-related gene regulation (5 papers), Liver physiology and pathology (4 papers), Multiple Myeloma Research and Treatments (4 papers), Bone health and treatments (4 papers) and Epigenetics and DNA Methylation (4 papers). The work is most often cited by research in Urology (405 citations), Rheumatology (913 citations), Genetics (507 citations), Orthopedics and Sports Medicine (385 citations) and Molecular Biology (3.0k citations). Ellen Filvaroff has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Richard A.D. Carano, Rik Derynck, Adrian Erlebacher, Stephen E. Gitelman, Min Bao, Jeffrey L. Cleland, Stuart Bunting, Hope Steinmetz, J. M. Hoeffel and H. P. Redmond. Their work appears in journals such as Annals of Oncology, Molecular and Cellular Biology, Human Immunology, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact